Form 4: Exagen Inc. CFO Jeffrey G. Black Reports Acquisition of Shares and Stock Options

Chief Financial Officer Jeffrey G. Black of Exagen Inc. reports the acquisition of 15,000 shares of common stock and 10,000 stock options on February 21, 2025.

Summary

• On February 21, 2025, Jeffrey G. Black, the Chief Financial Officer of Exagen Inc., acquired 15,000 shares of common stock.
• These shares were awarded as restricted stock units under the company's 2019 Incentive Award Plan.
• Each restricted stock unit represents a contingent right to receive one share of Exagen's common stock.
• The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 21, 2025, contingent upon continued service.
• Black also acquired 10,000 stock options with an exercise price of $3.58.
• These options vest over time, with 25% vesting on February 21, 2026, and the remainder vesting monthly thereafter, also contingent upon continued service.
• As of February 21, 2025, Black directly owns 289,492 shares of Exagen Inc. common stock.
• The stock option may become fully vested upon a qualifying termination of employment in connection with a change in control.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of restricted stock units and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over several years, indicating a long-term commitment from the CFO.

Industry Context

Stock option and restricted stock grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Equity compensation packages, including stock options and restricted stock units, are standard practice for CFOs in publicly traded companies, such as Exagen Inc.
• Companies like Adaptive Biotechnologies and Myriad Genetics, which are also in the diagnostics space, use similar equity-based compensation to incentivize their executives.
• The vesting schedules, typically spanning 3-4 years, are also in line with industry norms to ensure long-term commitment and alignment with company performance.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates